The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing
about
Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advancesCombination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunitiesUnlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapyRadiation meets immunotherapy - a perfect match in the era of combination therapy?Antitumor immunity induced after α irradiationVaccines as monotherapy and in combination therapy for prostate cancer.Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways.Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.Exploiting synergy: immune-based combinations in the treatment of prostate cancer.Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.Therapeutic cancer vaccines: current status and moving forward.Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitorsClinical evaluation of TRICOM vector therapeutic cancer vaccinesIn the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.Combining radiation and immunotherapy for synergistic antitumor therapy.Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challengesOrganizing pneumonia after stereotactic ablative radiotherapy of the lung.Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancerCancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trialSublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation.Prostate cancer and immunoproteome: awakening and reprogramming the guardian angels.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Immunomodulatory effects of radiation: what is next for cancer therapy?Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment.Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases.Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.[Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity].
P2860
Q26827475-92ADED10-61CC-4C1B-B203-8B0ACEBAB885Q26851710-3AEC9A58-5CDA-41DB-B082-A73E1B9984B9Q27001216-2C2E4547-4A21-4F2C-A9B9-A3462138369DQ27005913-FF298B72-F60D-4E67-B816-77E28EBD7A69Q33891246-6D50B881-A927-4BCB-842E-9167CD1A1FFCQ34039068-FB1614CC-797F-4DD3-8721-557F83DA0821Q34184469-B8DA8E10-21E7-4135-92FA-762605D76C1BQ34438000-AD451CBC-17BF-4E63-9EFB-68973EF17200Q34687216-74B30799-7547-4AC9-AC49-83C6DD64941DQ34876404-799C025D-EB5A-43D6-B667-1AAACBCA573BQ35057029-13983E11-EE92-4C0E-8C33-48F70DE6B79BQ35894347-9FF20347-36F9-4BB4-9F8E-86CA2C3D8604Q35922726-FB633AF0-D722-4FDE-9AC0-2F35BE4E3515Q35975387-AB943B19-57E7-4132-8301-504BFA45E832Q36099965-2F7B3642-1E77-495B-B075-BD2208F7C6E2Q36210670-3024F918-D006-4E7B-873D-2CCE01CE7E21Q36326598-F8EA8BB1-1F36-45CF-8E52-0FEC865DA338Q36326713-6BDC5670-6CA1-45CB-9DDE-4C92069D1D50Q36346363-E40E376B-AEB0-44F8-9978-FFB96178379EQ36820371-988C889C-1663-4A58-A0E8-54B44AFB1A1BQ37406706-3A0C771E-55EC-44BB-9254-4839A52B59A8Q37660302-FCEDF9F7-9E13-4082-A83F-612879FD48E6Q37684364-54CDEC12-189C-45A0-B6A0-5D22E62F3359Q37686296-675D71CE-EE99-479E-A520-42E6C33E62D9Q38000961-E42B2A6F-CCF1-4187-AEC5-17AB82ADBA0BQ38600417-C74F6A43-61D5-4BBC-BAFC-39BA96446943Q38654155-89D1CEFA-538C-478E-9AFC-4130021CDA31Q38981347-80C495ED-246E-4885-BD08-2F6F930926E4Q38995718-F7EC49D5-7AF4-47F6-9258-B2165967D3FEQ39206316-F269AECD-A84C-4A7C-97C3-BEAD5E00EFFFQ40229039-79E6473C-9361-42A3-9469-BB1035966314Q47403025-43766564-1865-4543-9A1E-FCD0F0E71B0EQ54025029-2A65DC9A-5E3F-4765-91C4-99694371FC69
P2860
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The use of chelated radionucli ...... nhance T cell-mediated killing
@ast
The use of chelated radionucli ...... nhance T cell-mediated killing
@en
type
label
The use of chelated radionucli ...... nhance T cell-mediated killing
@ast
The use of chelated radionucli ...... nhance T cell-mediated killing
@en
prefLabel
The use of chelated radionucli ...... nhance T cell-mediated killing
@ast
The use of chelated radionucli ...... nhance T cell-mediated killing
@en
P2093
P2860
P1476
The use of chelated radionucli ...... nhance T cell-mediated killing
@en
P2093
Chang H Paik
Elizabeth K Wansley
James W Hodge
Jeffrey Schlom
Jorge A Carrasquillo
Kevin Camphausen
Mala Chakraborty
Michael D Becker
William F Goeckeler
P2860
P304
P356
10.1158/1078-0432.CCR-08-0335
P407
P577
2008-07-01T00:00:00Z